Clinical utility of a panfungal polymerase chain reaction assay for invasive fungal diseases in patients with haematologic disorders

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 331-339

  Sugawara, Yumiko ^a   Nakase, Kazunori ^a   Nakamura, Akiko ^a   Ohishi, Kohshi ^a   Sugimoto, Yuka ^a   Fujieda, Atushi ^a   Monma, Fumihiko ^a   Suzuki, Kei ^a   Masuya, Masahiro ^a   Matsushima, Yoshiko ^a   Wada, Hideo ^a   Nobori, Tsutomu ^a   Katayama, Naoyuki ^a  

^a MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Haematologic disorder; Invasive fungal disease; Polymerase chain reaction

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MICAFUNGIN; RNA 18S;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; ASPERGILLUS USTUS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CUNNINGHAMELLA; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; FEMALE; FUNGAL DETECTION; FUSARIUM; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFECTION RISK; LUNG BIOPSY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; PANFUNGAL POLYMERASE CHAIN REACTION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHIZOPUS; RHODOTORULA; SCEDOSPORIUM APIOSPERMUM; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; DNA, FUNGAL; FEMALE; FUNGEMIA; HEMATOLOGIC DISEASES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MYCOSES; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SPECIES SPECIFICITY; YOUNG ADULT;

EID: 84875257680     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12078     Document Type: Article

References (43)

1. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88-100.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
3. Aisner J, Schimpff SC, Wiernik PH. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977;86:539-43.
4. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computerized tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
5. Duthie R, Denning DW. Aspergillus fungemia: report of two cases and review. Clin Infect Dis 1995;20:598-605.
6. Kami M, Tanaka Y, Ogawa S, Kanda Y, Honda H, Chiba S, Mitani K, Yazaki Y, Hirai H. The limitation of the circulating Aspergillus antigen detection methods for BMT recipients. Bone Marrow Transplant 1998;22:832-3.
7. Marr KA, Balajee SA, Mclaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190:641-9.
8. Karageorgooulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-d-glucan assay for the diagnosis of invasive fungal infections: a meta analysis. Clin Infect Dis 2011;52:750-70.
9. Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis. J Clin Microbiol 1996;34:2464-8.
10. Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997;35:1353-60.
11. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005;41:521-6.
12. Richardson M, Lass-Flori C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14:5-24.
13. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011;11:142-51.
14. Hebart H, Löffler J, Reitze H, et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 2000;111:635-40.
15. Lass-Flörl C, Aigner J, Gunsilius E, Petzer A, Nachbaur D, Gastl G, Einsele H, Löffler J, Dierich MP, Würzner R. Screening for Aspegillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 2001;113:180-4.
16. McLintock LA, Jones BL. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br J Haematol 2004;126:289-97.
17. Jordanides NE, Allan EK, McLintock LA, Copland M, Devaney M, Stewart K, Parker AN, Johnson PR, Holyoake TL, Jones BL. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant 2005;35:389-95.
18. Ribeiro P, Costa F, Monteiro A, et al. Polymerase chain reaction screening for fungemia and/or invasive fungal infections in patients with hematologic malignancies. Support Care Cancer 2006;14:469-74.
19. Khot PD, Fredricks DN. PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther 2009;7:1201-21.
20. Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P, Halliday C. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 2007;45:380-5.
21. Pauw BD, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal diseases from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
22. Nakamura A, Wada H, Ikejiri M, et al. Efficacy of procalcitonin in the early diagnosis of bacterial infection in a critical care unit. Shock 2009;31:586-91.
23. Nakamura A, Sugimoto Y, Ohishi K, et al. Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropenia. J Clin Microbiol 2010;48:2030-6.
24. Hue FX, Huerre M, Rouffault MA, de Bievre C. Specific detection of fusarium species in blood and tissues by a PCR technique. J Clin Microbiol 1999;37:2434-8.
25. Imhof A, Balajee A, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39:743-6.
26. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malingnancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39:425-9.
27. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008;46:1733-7.
28. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005;49:5157-9.
29. Louie T, El Baba F, Shulman M, Jimenez-Lucho V. Endogenous endophthalmitis due to Fusarium: case report and review. Clin Infect Dis 1994;18:585-8.
30. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.
31. Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K, Wagener MM, Singh N. Infections due to Scedosporium apiospermum and Scedosporium profificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005;40:89-99.
32. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005;43:476-8.
33. Asano-Mori Y, Kanda Y, Oshima K, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 2008;61:411-6.
34. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implication for management. Blood 1997;90:999-1008.
35. Kapp M, Schargus M, Deuchert T, et al. Endophathalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient. Transpl Infect Dis 2011;13:374-9.
36. Garcia-Suarez J, Gomez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses 2011;54:318-24.
37. Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad II. Aspergillus terreus: an emerging Apmphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004;101:1594-600.
38. Verweij PE, Van den Bergh MF, Rath PM, De Pauw BE, Voss A, Meis JF. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol 1999;37:1606-9.
39. Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infection among transplant recipients. Emerg Infect Dis 2006;12:403-8.
40. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 2008;46:541-6.
41. Rosmaninho A, Torres T, Velho G, Lopes V, Amorim I, Selores M. Paecilomyces lilacinus in transplant patients: an emerging infection. Eur J Dermatol 2010;20:643-4.
42. Szymanska J. Evaluation of mycological contamination of dental unit waterlines. Ann Agric Environ Med 2005;12:153-5.
43. Loeffler J, Barnes R, Donnelly JP. Standardization of Aspergillus PCR diagnosis. Bone Marrow Transplant 2012;47:299-300.